Company intelligence / Profile preview
TARIS Biomedical
Lexington, Massachusetts, United Statestarisbiomedical.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TARIS developed a first-in-class clinical stage platform to evaluate novel, locally delivered therapeutics to patients with bladder cancer. Their lead program TAR-200 (GemRIS) received FDA Fast Track designation for treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative intent therapy.
- Therapeutic areas
- OncologyUrologyNephrology
- Modalities
- Drug delivery systemsLocal drug delivery
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on TARIS Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TARIS Biomedical.